Tag Archives: nvro

IPO Stock Watch: Nevro Soars On Q1 Beat, FDA Approval

Small medical-device firm Nevro (NVRO) soared to a new high of 58.87 Monday, eventually closing up 17.6% at 53.33 in more than eight times the average volume. The market seemed to be responding to both its Q1 earnings beat Monday as well as the late-Friday FDA approval of its Senza spinal-cord stimulator for treating chronic pain. Nevro reported Q1 revenue of $9.7 million, up 45% from the year-earlier quarter and about $1.4 million above analysts’

IPO Stock Watch: Medical Device Maker Nevro Hits High

JPMorgan raised its price target on Nevro (NVRO) to 42 from 34 and the stock rose 13% Monday, closing at an all-time high of 39.37. Nevro develops and markets an implantable spinal cord stimulation system called Senza, designed to treat chronic pain in the back and legs. The company raised $126 million on its Nov. 6 IPO, which priced at 18, above the estimated range of 15 to 17. In June, Nevro submitted its premarket approval application to the

IPO Calendar: Medical Device Maker Nevro Jumps in IPO

Medical device company Nevro rose 40% in its stock market debut Thursday, and its initial public offering raised $126 million. Nevro (NVRO) develops and markets an implantable spinal cord stimulation system, called Senza, designed to treat chronic pain in the back and legs. In the IPO, Nevro sold 7 million shares, up from 6.25 million originally planned, at 18. That was above the estimated range of 15 to 17. Shares closed at 25.19 in the stock